Effects of different dose of FK506 on endocrine function of pancreatic islets and damage of beta cells of pancreatic islets in a Wistar rat model

Immunopharmacology and Immunotoxicology

Volumn 32, Issue 2, 2010, Pages 333-338

  Li, Feng ^a   Li, Qingyuan ^a  

^a Binzhou Medical University   (China)

Author keywords

C peptide; Dose; FK506; Glucose; Insulin

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET DISEASE; PRIORITY JOURNAL; RAT; SECRETORY GRANULE; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; C-PEPTIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; RATS; RATS, WISTAR; TACROLIMUS;

RATTUS NORVEGICUS;

EID: 77952225598     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923970903358191     Document Type: Article

References (24)

1. Staatz CE, Taylor PJ, Lynch SV, et al. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation. Liver Transpl 2004 Apr;10(4):506-512
2. OSeaghdha CM, McQuillan R, Moran AM, et al. Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection. Clin Transplant 2009 Aug;23(4):462-468
3. Liu F, Li Y, Lan X, Wei YG, et al. Tacrolimus dosage requirements in living donor liver transplant recipients with small-for-size grafts. World J Gastroenterol 2009 Aug 21;15(31):3931-3936
4. Ye F, Ying-Bin X, Yu-Guo W, et al. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis. J Heart Lung Transplant 2009 Jan; 28(1): 58-66.
5. Gruessner RW, Kandaswamy R, Humar A. Calcineurin inhibitorand steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 2005 May 15; 79(9):1184-1189
6. Celik MR, Lederer DJ, Wilt J, et al. Tacrolimus and azathioprine versus cyclosporine and mycophenolate mofetil after lung transplantation: a retrospective cohort study. J Heart Lung Transplant 2009 Jul;28(7):697-703. Epub 2009 May 13.
7. Marchewka Z, Ku?niar J, Zynek-Litwin et al. Kidney graft function in long-term cyclosporine and tacrolimus treatment: comparative study with nephrotoxicity markers. Transplant Proc 2009 Jun;41(5):1660-1665
8. Videla CO. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy. Transplant Proc 2009 Jul-Aug;41(6):2659-2663
9. Staatz CE, Taylor PJ, Lynch SV, et al. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation. Liver Transplant 2004 Apr;10(4):506-512
10. Woodside KJ, Nichols SD, Hunter GC, et al. Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile. Transplant Proc 2005 May;37(4):1877-1879
11. Basi-Juki N, Juri I, Kes P, et al. [Arterial hypertension in renal transplant recipients]. Acta Med Croatica 2007 Apr;61(2):171-176
12. Kim HC, Hwang EA, Han SY. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. Transplant Proc 2004 Sep;36(7):2082-3]
13. Al Masri O, Fathallah W, Quader S., et al. Recovery of tacrolimusassociated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient-case report and review of the literature. Pediatr Transplant 2008 Dec;12(8):914-917 Epub 2008 May 23.
14. Ginsburg PM, Thuluvath PJ. Diarrhea in liver transplant recipients: etiology and management. Liver Transpl 2005 Aug;11(8):881-890
15. van Hooff JP, Christiaans MH, van Duijnhoven EM. Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation 2005 Jun 15;79(11):1465-1469
16. Tory R, Sachs-Barrable K, Goshko CB, et al. Tacrolimusinduced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. Transplantation 2009 Jul 15;88(1):62-68
17. Forgacs B, Merhav HJ, Lappin J, et al. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc 2005 May;37(4):1912-1914
18. Mazali FC, Lalli CA, Alves-Filho G, et al. Posttransplant diabetes mellitus: incidence and risk factors. Transplant Proc 2008 Apr;40(3):764-766
19. Salifu MO, Tedla F, Aytug S, et al. Posttransplant diabetes and hypertension: pathophysiologic insights and therapeutic rationale. Curr Diab Rep 2008 Jun;8(3):221-227
20. Jardine AG. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int 2005 Apr;18(4):379-384
21. Burroughs TE, Lentine KL, Takemoto SK, et al. Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. Clin J Am Soc Nephrol 2007 May;2(3):517-523
22. Li QY, Li F, Sun JH, Chi YY, et al. Mechanisms of diabetes mellitus induced with FK506 in SD rats models. Immunopharmacol Immunotoxicol 2009 Jul 28. [Epub ahead of print]
23. Zhang M, Lv XY, Li J, et al. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res 2008 Jan;2008:704045.
24. Juan CC, Shen YW, Chien Y, et al. Insulin infusion induces endothelin-1-dependent hypertension in rats. Am J Physiol Endocrinol Metab 2004 Nov;287(5):E948-54. Epub 2004 Jun.